DK0963980T3 - 1,2,4,-trianzinderivat, fremstilling deraf og anvendelse deraf som referencemarkør til bestemmelse af "lamotrigins"-renhed og stabilitet - Google Patents

1,2,4,-trianzinderivat, fremstilling deraf og anvendelse deraf som referencemarkør til bestemmelse af "lamotrigins"-renhed og stabilitet

Info

Publication number
DK0963980T3
DK0963980T3 DK99200695T DK99200695T DK0963980T3 DK 0963980 T3 DK0963980 T3 DK 0963980T3 DK 99200695 T DK99200695 T DK 99200695T DK 99200695 T DK99200695 T DK 99200695T DK 0963980 T3 DK0963980 T3 DK 0963980T3
Authority
DK
Denmark
Prior art keywords
trianzin
lamotrigine
purity
derivative
stability
Prior art date
Application number
DK99200695T
Other languages
Danish (da)
English (en)
Inventor
Lorraine Mary Edmeades
Nigel Arthur Griffith-Skinner
Derek Anthony Hill
Graham Thornton Hill
Terrence William Packham
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0963980(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0963980T3 publication Critical patent/DK0963980T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK99200695T 1998-06-10 1999-03-10 1,2,4,-trianzinderivat, fremstilling deraf og anvendelse deraf som referencemarkør til bestemmelse af "lamotrigins"-renhed og stabilitet DK0963980T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
DK0963980T3 true DK0963980T3 (da) 2002-09-16

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99200695T DK0963980T3 (da) 1998-06-10 1999-03-10 1,2,4,-trianzinderivat, fremstilling deraf og anvendelse deraf som referencemarkør til bestemmelse af "lamotrigins"-renhed og stabilitet

Country Status (31)

Country Link
US (1) US6333198B1 (de)
EP (2) EP1170588A1 (de)
JP (1) JP2989189B1 (de)
KR (1) KR100322354B1 (de)
CN (2) CN1238454A (de)
AP (3) AP9901481A0 (de)
AR (1) AR014074A1 (de)
AT (1) ATE218552T1 (de)
AU (1) AU2031999A (de)
BR (1) BR9900984A (de)
CA (1) CA2265194C (de)
DE (1) DE69901656T2 (de)
DK (1) DK0963980T3 (de)
EA (1) EA000666B1 (de)
ES (1) ES2178342T3 (de)
GB (1) GB9812413D0 (de)
HR (1) HRP990074A2 (de)
HU (1) HUP9900592A3 (de)
ID (1) ID22957A (de)
MA (1) MA24777A1 (de)
NO (2) NO991151L (de)
NZ (1) NZ334590A (de)
PE (1) PE20000332A1 (de)
PL (1) PL331870A1 (de)
PT (1) PT963980E (de)
SG (1) SG85628A1 (de)
SI (1) SI0963980T1 (de)
TR (1) TR199900520A2 (de)
UY (1) UY25946A1 (de)
YU (1) YU12399A (de)
ZA (1) ZA991951B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB2372988B (en) * 2000-01-03 2004-04-07 Rpg Life Sciences Ltd A process for the preparation of 6-(2,3-Dichlorophenyl)-1,2,4- Triazine-3,5-Diamine, commonly known as Lamotrigine
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
CA2433284A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
EP1309558A1 (de) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Aspartat-derivat von amlodipine als kalzium-kanal antagonist
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
AP2003002820A0 (en) 2000-12-29 2003-06-30 Pfizer Ltd "Process for making amlodipine maleate"
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
EP1309557B9 (de) 2000-12-29 2006-11-15 Pfizer Limited Amlodipin-hemimaleat
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
WO2003080065A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
DE602005015174D1 (de) * 2004-04-21 2009-08-13 Teva Pharma Verfahren zur herstellung von montelukast-natrium
TW200613294A (en) * 2004-04-26 2006-05-01 Teva Gyogyszergyar Reszvenytarsasag Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) * 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
WO2006004976A2 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of atomoxetine hydrochloride
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006012385A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Crystalline mycophenolate sodium
WO2006020348A2 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US7629461B2 (en) * 2004-09-04 2009-12-08 Teva Pharmaceutical Industries Ltd Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
WO2006045120A2 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
CA2591666A1 (en) * 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
EP1874754A1 (de) * 2005-03-14 2008-01-09 Teva Pharmaceutical Industries Ltd Reines duloxetinhydrochlorid
MX2007010268A (es) * 2005-04-05 2008-02-19 Teva Pharm Fine Chemicals Srl Clorhidrato de atomoxetina estable, un proceso para la preparacion del mismo, y un control analitico de su estabilidad.
WO2006108151A1 (en) * 2005-04-06 2006-10-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
EP1869007A1 (de) * 2005-04-14 2007-12-26 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von quetiapinfumaraten
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
KR20090019016A (ko) * 2005-05-10 2009-02-24 테바 파마슈티컬 인더스트리즈 리미티드 3-카르바모일메틸-5-메틸 헥산산의 광학 분할
MX2007000525A (es) * 2005-05-10 2007-03-28 Teva Pharma Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella.
WO2006122258A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
WO2006127933A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
WO2007002722A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. Synthesis of anastrozole and purification of one of its intermediate
EP1896398A2 (de) * 2005-06-27 2008-03-12 Sicor Inc. Verunreinigung des anastrozol-zwischenprodukts und verwendungen dafür
JP2008510840A (ja) * 2005-07-05 2008-04-10 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストの精製
CA2619576C (en) * 2005-08-16 2011-12-06 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
US7446220B2 (en) * 2005-09-19 2008-11-04 Teva Pharmaceutical Industries Ltd. Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
CA2626715A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for preparing darifenacin hydrobromide
WO2007126886A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceuticals Usa, Inc. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
WO2007139933A2 (en) * 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EP2071032A3 (de) * 2006-05-31 2009-07-08 Teva Pharmaceutical Industries Ltd Enzymatische Auflösung für die Herstellung von Pregablin-Zwischenprodukten
EP1912931A2 (de) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd. (s)-prägabalin-nitril-präparat
SI2032712T1 (sl) * 2006-06-29 2010-06-30 Ivax Pharmaceuticals Sro Regulacija proizvodnje kislinskega metabolita
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
EP2054396A1 (de) * 2006-08-14 2009-05-06 Lonza Ag Verfahren zur herstellung von lamotrigin
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
KR101036536B1 (ko) * 2007-03-22 2011-05-24 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸 헥산산의 합성
EP2024506A1 (de) * 2007-04-11 2009-02-18 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Verfahren zur reduzierung des verunreinigungslevels bei der myophenolsäure-fermentierung
EP2069320A2 (de) * 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Verfahren zur synthese von ramelteon und seinen zwischenprodukten
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
US8067423B2 (en) * 2007-10-23 2011-11-29 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
WO2009056993A2 (en) * 2007-11-01 2009-05-07 Teva Pharmaceutical Industries Ltd. A process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
EP2252574A1 (de) * 2008-03-06 2010-11-24 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von dimer-unreinheitsfreiem o-desmethylvenlafaxin
EP2297090A1 (de) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Stereoselektive enzymatische synthese von (s)- bzw. (r)-iso-butyl-glutarsäure
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CA2795023A1 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625169A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
EP0021120B1 (de) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-Diamino-1,2,4-triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zusammensetzungen sie enthaltend
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
RU2145602C1 (ru) * 1994-12-30 2000-02-20 Де Вэллкам Фаундейшн Лимитед Способы получения ламотриджина, промежуточные соединения и способ получения фармацевтической композиции
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
PE20000332A1 (es) 2000-04-10
SG85628A1 (en) 2002-01-15
HU9900592D0 (en) 1999-04-28
EP1170588A1 (de) 2002-01-09
TR199900520A3 (tr) 2000-01-21
KR100322354B1 (ko) 2002-02-07
HRP990074A2 (en) 2000-10-31
SI0963980T1 (en) 2002-12-31
NZ334590A (en) 2000-07-28
NO991151D0 (no) 1999-03-10
PL331870A1 (en) 1999-12-20
HUP9900592A2 (hu) 2000-04-28
AP2001002286A0 (en) 2001-12-31
AP9901481A0 (en) 1999-03-31
AR014074A1 (es) 2001-01-31
EP0963980A2 (de) 1999-12-15
US6333198B1 (en) 2001-12-25
AU2031999A (en) 2000-01-06
JP2000009714A (ja) 2000-01-14
EA000666B1 (ru) 2000-02-28
NO20032753D0 (no) 2003-06-17
NO991151L (no) 1999-12-13
ATE218552T1 (de) 2002-06-15
EA199900159A1 (ru) 1999-12-29
HUP9900592A3 (en) 2002-04-29
MA24777A1 (fr) 1999-10-01
JP2989189B1 (ja) 1999-12-13
ZA991951B (en) 1999-08-16
CN1306210A (zh) 2001-08-01
PT963980E (pt) 2002-10-31
AP0102286A0 (en) 2000-09-10
NO20032753L (no) 1999-12-13
UY25946A1 (es) 2000-12-29
EP0963980B1 (de) 2002-06-05
CN1238454A (zh) 1999-12-15
ES2178342T3 (es) 2002-12-16
DE69901656T2 (de) 2003-01-30
KR20000005611A (ko) 2000-01-25
GB9812413D0 (en) 1998-08-05
EP0963980A3 (de) 2000-05-31
ID22957A (id) 1999-12-23
TR199900520A2 (en) 2000-01-21
DE69901656D1 (de) 2002-07-11
BR9900984A (pt) 2000-05-02
YU12399A (sh) 2002-08-12
CA2265194C (en) 2000-10-10

Similar Documents

Publication Publication Date Title
DK0963980T3 (da) 1,2,4,-trianzinderivat, fremstilling deraf og anvendelse deraf som referencemarkør til bestemmelse af "lamotrigins"-renhed og stabilitet
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
DK1128729T3 (da) Herbicid sammensætning
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
HUS1100025I1 (hu) N-(fenil-acetil)-N-(2,6-xilil)-metil-alaninát(benalaxil) alapú szinergetikus fungicid készítmények és alkalmazásuk
ID26936A (id) Komposisi herbisida konsentrat
IS2071B (is) Ný 3-arýl-2-hýdroxýprópíonsýruafleiða (I)
FR2775183B1 (fr) Prothese inter-epineuse
NO20004240D0 (no) Formuleringer
EE200000693A (et) Uudsed makroosakeste formulatsioonid
ATE224703T1 (de) Brauseformulierungen
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
PT1130966E (pt) Formulacoes antiparasitarias
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
DE59900501D1 (de) Feste, schnellzerfallende cetirizin-formulierungen
DE69905968D1 (de) Eine Fotoresistzusammensetzung
DK1461418T3 (da) Fremgangsmåde til fremstilling af 3-o-deacylated-4'-monophosphoryllipid a (3d-mla)
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
IS5562A (is) Nýjar díhýdroxýhexanósýru afleiður
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
EE200000447A (et) 1,3,4-oksadiasolooni derivaadid
AR014500A1 (es) Un procedimiento para la preparacion de derivados de dicarboxilato de piridina
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse